Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology.
Phillips R. et al, (2026), Br J Cancer, 134, 289 - 294
Single-cell proteomics sheds light on neutrophil diversity in glioblastoma.
Skolariki A. and Parkes EE., (2025), Nat Rev Immunol, 25
IGF-1 regulates cancer cell immune evasion in prostate cancer.
Nandakumar AM. et al, (2025), Sci Rep, 15
Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration.
Rosen LS. et al, (2025), J Immunother Precis Oncol, 8, 263 - 275
Interactions between cancer-associated fibroblasts and the extracellular matrix in oesophageal cancer.
Vadibeler S. et al, (2025), Matrix Biol, 139, 49 - 60
CINs of the cytoplasm: dissecting dsRNA signaling in chromosomal instability.
Skolariki A. et al, (2025), Mol Oncol, 19, 1561 - 1564
Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases.
Lawson NM. et al, (2025)
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.
Harrington K. et al, (2025), Future Oncol, 21, 195 - 200
Redefining PD1 as a guardian of stem-like T cells.
Jackson M. and Parkes EE., (2025), Nat Rev Immunol, 25
Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis.
Jackson A. et al, (2024), Lancet Oncol, 25, 1476 - 1486
cGAS-driven inflammation in chromosomally unstable oesophagogastric adenocarcinoma
Parkes EE. et al, (2024), ANNALS OF ONCOLOGY, 35, S908 - S908
Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study
Harrington KJ. et al, (2024), ANNALS OF ONCOLOGY, 35, S684 - S685
Targeting mitotic regulators in cancer as a strategy to enhance immune recognition.
Gregorczyk M. and Parkes EE., (2023), DNA Repair (Amst), 132
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Pencik J. et al, (2023), Mol Cancer, 22
Non-cell-autonomous cancer progression from chromosomal instability.
Li J. et al, (2023), Nature, 620, 1080 - 1088